Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6
Speaking of SurgOnc
by Annals of Surgical Oncology
1M ago
Rick Greene, MD, discusses with Anthony Villano, MD, a review the American College of Surgeons Commission on Cancer Standard 5.6, which pertains to curative intent colon resections performed for cancer. Dr. Villano is author of "Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6." Dr. Villano is the Assistant Professor, Surgical Oncology, in the Department of Surgical Oncology, at Fox Chase Cancer Center in Philadelphia, PA ..read more
Visit website
Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer
Speaking of SurgOnc
by Annals of Surgical Oncology
2M ago
Rick Greene, MD, discusses with Jean-Nicolas Vauthey, MD, a comparison of different surgical approaches to synchronous liver metastases from rectal cancer and their analysis of both clinicopathological and biological tumor factors associated with completion of the reverse approach. Professor Vauthey is the senior author of, “Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.” Dr. Vauthey is Professor of Surgery and Chief of the Hepato-Pancreato-Biliary Section, and the Dallas/Fort Worth Living Legend Chair of Cancer Research in ..read more
Visit website
Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?
Speaking of SurgOnc
by Annals of Surgical Oncology
3M ago
Rick Greene, MD, discusses with Patricio M. Polanco, MD, an analysis of three hospital designations, as well as volume status, and their effect on the delivery of care and survival outcomes using a cancer registry database of the second largest state in the USA. Dr. Polanco is co-corresponding author of, “Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter ..read more
Visit website
Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study
Speaking of SurgOnc
by Annals of Surgical Oncology
4M ago
Rick Greene, MD, discusses with Eduardo A. Vega, MD, definitions reported on of benchmark values for gallbladder cancer surgery across an international population as well as geographic differences in gallbladder cancer surgery across multiple continents. Dr. Vega is the senior author of, “Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study.” Dr. Vega is Assistant Professor of Surgery at Boston University School of Medicine and Hepato-Bilio-Pancreatic surgeon in the Department of Surgery at St. Elizabeth’s Medical Center, Boston, MA. Full arti ..read more
Visit website
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
Speaking of SurgOnc
by Annals of Surgical Oncology
5M ago
Rick Greene, MD, discusses with Susan Tsai, MD, MHS, the results of an analysis examining the efficacy of second-line gemcitabine/nab-paclitaxel (GnP) after first-line FOLFIRINOX in the neoadjuvant setting among patients with operable pancreatic cancer who were treated with a total neoadjuvant approach. Dr. Tsai is the senior author of, “CA19-9 Response to First-line Neoadjuvant FOLFIRINOX and Second-line Gemcitabine/nab- Paclitaxel in Patients with Operable Pancreatic Cancer.” Dr. Tsai is Professor of Surgery and Chief of the Division of Surgical Oncology at The Ohio State University Comprehe ..read more
Visit website
Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients
Speaking of SurgOnc
by Annals of Surgical Oncology
6M ago
Rick Greene, MD, discusses with Sean Cleary, MD, cytoreductive hepatectomy for neuroendocrine tumor liver metastases; specifically, perioperative outcomes and operative trends, rates and duration of symptomatic relief, and long-term survival and predictors of prognosis. Dr. Cleary is the senior author of, “Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.” Dr. Cleary is the Bernard and Ryna Langer Chair of the Division of General Surgery in the Department of Surgery at the University of Toronto, Toronto, Canada ..read more
Visit website
Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects
Speaking of SurgOnc
by Annals of Surgical Oncology
7M ago
Rick Greene, MD, discusses with Anna Weiss, MD, the evidence-based treatments available for the adverse effects of endocrine therapy that can be experienced by breast cancer patients, including clear treatment algorithms for genitourinary syndrome of menopause (GSM), which can be overlooked by providers. Dr. Weiss is the senior author of, “Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects.” Dr. Weiss is Associate Professor of Surgery and Medicine, and Director of the Wilmot Cancer Institute Comprehensive Breast Cancer Program at Plut ..read more
Visit website
Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT
Speaking of SurgOnc
by Annals of Surgical Oncology
10M ago
Rick Greene, MD, discusses with Jesse Selber MD, MPH, MHCM, FACS, the use of ChatGPT and explores questions regarding the potential of artificial intelligence (AI) in surgery and its opportunities, challenges, and  possible role in surgery. Dr. Selber is the senior author of the article entitled "Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT.” Dr. Selber is Surgical Service Line Chief and Professor of Plastic Surgery at Corewell Health, East outside of Detroit, Michigan. https://link.springer.com/article/10.1245/s10434-0 ..read more
Visit website
A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases
Speaking of SurgOnc
by Annals of Surgical Oncology
11M ago
Rick Greene, MD, discusses with Dr. Giammauro Berardi, MD, PhD, FEBS, the outcomes of a large cohort of patients undergoing upfront surgery for resectable colorectal liver metastases (CRLM) to analyze the predictability and probability of early treatment failure using clinicopathological characteristics. Dr. Berardi is author of, “A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases.” Dr. Berardi is attending at the Department of HPB Surgery and Liver Transplantation of the San Camillo Forlanini Hospital, Rome, Italy, and previo ..read more
Visit website
Surgical Approach Does Not Affect Return to Intended Oncologic Therapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched Study
Speaking of SurgOnc
by Annals of Surgical Oncology
1y ago
Dr. Rick Greene and Dr. Fadi Dahdaleh discuss the effect of operative approach on overall readiness to commence adjuvant therapy in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy, hypothesizing that minimally invasive pancreaticoduodenectomy improves rates and time to return to intended oncologic therapy compared with open pancreaticoduodenectomy. Dr. Dahdaleh is author of “Surgical Approach does not Affect Return to Intended Oncologic Therapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched Study.” Dr. Dahdaleh is an atte ..read more
Visit website

Follow Speaking of SurgOnc on FeedSpot

Continue with Google
Continue with Apple
OR